Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials.

Rollin-Sillaire, Adeline; Breuilh, Laetitia; Salleron, Julia; Bombois, Stéphanie; Cassagnaud, Pascaline; Deramecourt, Vincent; Mackowiak, Marie-Anne; Pasquier, Florence

Rollin-Sillaire, Adeline; Breuilh, Laetitia; Salleron, Julia; Bombois, Stéphanie; Cassagnaud, Pascaline; Deramecourt, Vincent; Mackowiak, Marie-Anne; Pasquier, Florence.

Affiliation

Rollin-Sillaire A; Univ Lille Nord de France, UDSL, Lille, France. adeline.rollin@chru-lille.fr

Br J Clin Pharmacol ; 75(4): 1089-97, 2013 Apr.

Article in En | MEDLINE | ID: mdl-22891847

Subject(s)

Alzheimer Disease/diagnosis; Patient Selection; Randomized Controlled Trials as Topic/standards; Aged; Aged, 80 and over; Double-Blind Method; Humans; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Patient Selection / Alzheimer Disease Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Aged80 / Humans / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2013 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google